Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Á. Sanz, Miguel; Montesinos, Pau; Rayón, Chelo; Holowiecka, Alexandra; de la Serna, Javier; Milone, Giuseppe; de Lisa, Elena; Brunet, Salut; Rubio, Vicente; Ribera, Josep‐María; Rivas, Concha; Krsnik, Isabel; Bergua, Juan; González, José; Diaz‐Mediavilla, Joaquín; Rojas, Rafael; Manso, F.; J. Ossenkoppele, Gert; D. González, José; Löwenberg, Bob

doi:10.1182/blood-2010-01-266007

Public

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Published in Blood • Apr 15, 2010

Authors:

Miguel Á. Sanz

Pau Montesinos

Chelo Rayón

Abstract

A risk-adapted strategy based on all-trans retinoic acid (ATRA) and anthracycline monochemotherapy (PETHEMA LPA99 trial) has demonstrated a high antileukemic efficacy in acute promyelocytic leukemia. We designed a new trial (LPA2005) with the objective of achieving stepwise improvements in outcome. ...

Subject

Idarubicin

Mitoxantrone

Cytarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!